Business ❯ Mergers and Acquisitions ❯ Pharmaceutical Industry ❯ Market Competition

Eli Lilly and Novo Nordisk

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

The deal brings an oral obesity candidate into Pfizer’s pipeline, with YaoPharma finishing Phase 1 in Australia before a planned handoff.